Compare CGEM & HLF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGEM | HLF |
|---|---|---|
| Founded | 2016 | 1980 |
| Country | United States | United States |
| Employees | 109 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2020 | 2004 |
| Metric | CGEM | HLF |
|---|---|---|
| Price | $20.77 | $11.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $30.13 | $18.00 |
| AVG Volume (30 Days) | 750.3K | ★ 1.6M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.33 |
| Revenue | N/A | ★ $5,037,500,000.00 |
| Revenue This Year | N/A | $4.97 |
| Revenue Next Year | $5.20 | $3.80 |
| P/E Ratio | ★ N/A | $35.42 |
| Revenue Growth | N/A | ★ 0.89 |
| 52 Week Low | $5.68 | $7.56 |
| 52 Week High | $23.19 | $20.40 |
| Indicator | CGEM | HLF |
|---|---|---|
| Relative Strength Index (RSI) | 49.46 | 46.64 |
| Support Level | $11.87 | $11.37 |
| Resistance Level | $23.19 | $13.09 |
| Average True Range (ATR) | 0.96 | 0.58 |
| MACD | -0.26 | -0.04 |
| Stochastic Oscillator | 51.40 | 53.62 |
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Herbalife Ltd is a health and wellness company. It provides health and wellness products in 95 markets through a direct-selling business model. Its product categories include Weight Management, Targeted Nutrition, Energy, Sports and Fitness, Outer Nutrition, and Literature, Promotional, and Other. Weight Management generates the majority of revenue, with products such as meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Products are manufactured at facilities in Changsha and Suzhou, China; Lake Forest, California; and Winston-Salem, North Carolina, as well as by third-party providers. Revenues reflect sales to Members across North America, Latin America, EMEA, Asia Pacific, and China.